the European Institute of Oncology
Published by:
Audio is brought to you by The ASCO Audio Journal of Oncology and Audiomedica
Interviews with leading investigators presenting new findings on: HRT lowering breast cancer risk, dexamethasone for multiple myeloma, sunitinib and sorafenib for renal cell cancer, child regimens for young adults with leukaemia, immunotherapy for head & neck cancer, and pazopanib & perifosine for renal cell cancer. Findings presented at the Chemotherapy Foundation Symposium XXV, November 6-10, 2007, New York.
RX-II: A Novel Agent for Immune Modulation Therapy for Head and Neck Cancer
Gregory Wolf, University of Michigan. An immune approach to treating cancer of the head and neck looks promising. Gregory Wolf told conference delegates at the Chemotherapy Foundation Symposium that clinical responses to a novel agent have been reported from Mexico, and that his group is now testing the same agent (IRX-II) in pilot studies. He talked with Peter Goodwin.
Adobe Flash player is required to listen
Pazopanib and Perifosine: New, Active Targeted Therapies in Renal Cancer
Robert Figlin, City of Hope Comprehensive Cancer Center, Los Angeles. Pazopanib and perifosine are two new agents that have performed well in phase II studies of renal cell carcinoma. Derek Thorne asked Robert Figlin about the data on these drugs, and about what doctors should make of the increasing number of targeted therapies emerging for kidney cancer.
Adobe Flash player is required to listen
Sunitinib and Sorafenib: Expanded Access Data in Renal Cell Cancer
Janice Dutcher, Our Lady of Mercy Medical Center, Bronx, NY. Encouraging clinical benefits have emerged among patients with renal cell cancer treated with sunitinib and sorafenib who do not fulfill the usual criteria for clinical trials with these tyrosine kinase inhibitors. Janice Dutcher told Peter Godwin about findings from an "expanded access" program.
Adobe Flash player is required to listen
Significant Drop in US Breast Cancer Incidence Linked to Reduction in Hormone Replacement Therapy
Peter Ravdin, from MD Anderson Cancer Center, Houston, speaking at the 2007 Chemotherapy Foundation Symposium. A large registry-based study has provided strong evidence that a significant drop in breast cancer incidence in 2003 was due to the decreased use of hormone replacement therapy. Derek Thorne heard more about the study and its implications when he interviewed Peter Ravdin in New York.
Adobe Flash player is required to listen
Low-Dose Dexamethasone Better For Newly Diagnosed Multiple Myeloma Treated With Lenalidomide
David Vesole, of St Vincent's Comprehensive Cancer Center, New York talking at the 2007 Chemotherapy Foundation Symposium. In newly diagnosed multiple myeloma, lenalidomide plus a lower dose of dexamethasone appears to be favorable for patients, and with a one-year survival rate of 96%, it could be the best result seen in this setting. During the New York symposium Derek Thorne put questions to David Vesole about his findings and their clinical implications.
Adobe Flash player is required to listen
Young Adults With Acute Lymphoblastic Leukemia: Better Success With Pediatric Regimens
Daniel DeAngelo, Dana-Farber Cancer Institute, Boston, talking at the 2007 Chemotherapy Foundation Symposium. Young adults with ALL may be treated more effectively by using chemotherapy regimens traditionally reserved for children, rather than by using therapies recommended for adults. This came out of a talk in New York given by Daniel DeAngelo, and he later discussed with Peter Goodwin his views and preliminary results from an ongoing trial, including dose-intense asparagine depletion therapy.
Adobe Flash player is required to listen
